A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.
The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.
Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.
The conversation discusses hair loss treatments, specifically using finasteride pills, RU58841 topically, and dermarolling twice a week. The user also mentions considering minoxidil and addressing a vitamin D deficiency, which may have contributed to reduced hair shedding.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Liquid minoxidil causes scalp flaking due to propylene glycol, leading some to consider switching to foam or PG-free liquid with applicators. Foam is often recommended for ease and effectiveness, while PG-free liquid is less common but can reduce irritation.
The conversation discusses hair loss treatment using finasteride, minoxidil chews, 0.5 dermarolling, 2% ketoconazole, and a silk bonnet. The user reports positive progress and plans to continue the regimen.
Eucapil/fluridil is discussed as a potential treatment for hair loss, with questions about its effectiveness and why it isn't a primary treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.
Users discuss experiencing hair shedding while using finasteride, with some noticing it later than expected. They express hope that the shedding is temporary and share experiences of natural shedding cycles.
The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.
The conversation humorously discusses hair loss treatments, focusing on finasteride and hair transplants, with references to public figures like Trump and Biden. It speculates on whether Trump has stopped using finasteride, noting his hair thinning and potential side effects.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A person dealing with hair loss is considering shaving their head, using scalp micropigmentation to cover a FUT scar, or trying a hair system. They are also contemplating treatments like minoxidil, finasteride, and dutasteride.
Fluridil is discussed as a potential topical alternative for hair loss for those experiencing side effects from finasteride. Some people have tried higher concentrations, but there's no clear consensus on its effectiveness.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
Fatty liver and related issues may influence hair loss conditions like Dupa/Aga. Treatments discussed include Minoxidil, finasteride, RU58841, myo-inositol, and L-glutamine.
Minoxidil can cause scalp flaking and dryness, often due to its alcohol content. Switching to foam minoxidil or using antifungal shampoos like Ketoconazole may help reduce these side effects.
People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.
Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.
3D printing hair for aesthetic purposes, highlighting its potential for cosplay and improving appearance. Users express excitement about the innovation and its impact on looks, especially for those experiencing hair loss.
Slaven Bilić's hair appears to use fibers, with noticeable gaps and color changes. He likely had a hair transplant but didn't use medications, leading to hair loss in non-transplanted areas.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.